Islet Beta-Cell Dysfunction Under Metabolic Stress

代谢压力下的胰岛β细胞功能障碍

基本信息

  • 批准号:
    10553637
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-01 至 2024-09-30
  • 项目状态:
    已结题

项目摘要

It is well established that chronic exposure of the pancreatic islet β-cells to metabolic stress (e.g., high glucose, palmitate and ceramide) induces metabolic dysfunction and loss of functional β-cell mass. Original and ongoing investigations from our laboratory have defined novel roles for Rac1, a small G-protein, in the pathogenesis of islet β-cell dysfunction under glucolipotoxic conditions. Based on published and compelling preliminary evidence, we now propose to test the overall hypothesis that metabolic stress promotes functional and transcriptional activation of Rac1 to promote intracellular oxidative stress, mitochondrial damage and eventual demise of the effete β-cell. We propose methodical investigations to identify key signaling proteins/factors in the Rac1 activation-deactivation cycle that might contribute to the metabolic and functional defects in the pancreatic β-cell. Studies designed herein will demonstrate regulatory roles and cross-talk between novel of guanine nucleotide dissociation inhibitors, namely GDI1 (RhoGDI) and GDI2 (LyGDI) (Aim 1) and scaffolding proteins/guanine nucleotide exchange factors (α4/β-PIX; Aim 2) in the functional activation of Rac1 in islet β-cells exposed to metabolic stress. Studies outlined in Aim 3 will investigate putative (NF-kB- mediated) mechanisms underlying transcriptional activation of Rac1 in islet β-cells under the duress of metabolic stress. Our goal in studies under Aim 4 is to demonstrate that aberrant transcriptional and functional activation of Rac1 leads to mitochondrial damage and islet dysfunction in an animal model of diet-induced obesity (DIO). Complementary studies will affirm contributory roles for intracellularly generated ceramide in the induction of islet dysfunction in our in vitro (Aims 1-3) and in vivo (Aim 4) model systems. Stated goals are accomplished via pharmacological, molecular biological, microscopic and lipidomics approaches in clonal β- (INS-1 832/13) cells, rodent, and human islets. Translational relevance of our project is enhanced by validation of our hypothesis in islets derived from T2DM human donors. The proposed studies are innovative and carry translational impact since they will identify putative mechanisms that dictate islet β-cell dysfunction in human diabetes. The long-standing expertise of the PI and his collaborators in this field will provide a unique opportunity to address these important aspects of islet function in health and diabetes. The data accrued from these investigations are also expected to provide actionable insights that will impact the prevention and treatment of T2DM in humans including our Veterans.
It is well established that chronic exposure of the pancreatic islet β-cells to metabolic stress (e.g., high glucose, palmitate and ceramide) induces metabolic dysfunction and loss of functional β-cell mass. Original and ongoing investigations from our laboratory have defined novel roles for Rac1, a small G-protein, in the pathogenesis of islet β-cell dysfunction under glucolipotoxic conditions. Based on published and compelling preliminary evidence, we now propose to test the overall hypothesis that metabolic stress promotes functional and transcriptional activation of Rac1 to promote intracellular oxidative stress, mitochondrial damage and eventual demise of the effete β-cell. We propose methodical investigations to identify key signaling proteins/factors in the Rac1 activation-deactivation cycle that might contribute to the metabolic and functional defects in the pancreatic β-cell. Studies designed herein will demonstrate regulatory roles and cross-talk between novel of guanine nucleotide dissociation inhibitors, namely GDI1 (RhoGDI) and GDI2 (LyGDI) (Aim 1) and scaffolding proteins/guanine nucleotide exchange factors (α4/β-PIX; Aim 2) in the functional activation of Rac1 in islet β-cells exposed to metabolic stress. Studies outlined in Aim 3 will investigate putative (NF-kB- mediated) mechanisms underlying transcriptional activation of Rac1 in islet β-cells under the duress of metabolic stress. Our goal in studies under Aim 4 is to demonstrate that aberrant transcriptional and functional activation of Rac1 leads to mitochondrial damage and islet dysfunction in an animal model of diet-induced obesity (DIO). Complementary studies will affirm contributory roles for intracellularly generated ceramide in the induction of islet dysfunction in our in vitro (Aims 1-3) and in vivo (Aim 4) model systems. Stated goals are accomplished via pharmacological, molecular biological, microscopic and lipidomics approaches in clonal β- (INS-1 832/13) cells, rodent, and human islets. Translational relevance of our project is enhanced by validation of our hypothesis in islets derived from T2DM human donors. The proposed studies are innovative and carry translational impact since they will identify putative mechanisms that dictate islet β-cell dysfunction in human diabetes. The long-standing expertise of the PI and his collaborators in this field will provide a unique opportunity to address these important aspects of islet function in health and diabetes. The data accrued from these investigations are also expected to provide actionable insights that will impact the prevention and treatment of T2DM in humans including our Veterans.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anjaneyulu Kowluru其他文献

Anjaneyulu Kowluru的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anjaneyulu Kowluru', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10337065
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10514628
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Islet Beta-Cell Dysfunction Under Metabolic Stress
代谢压力下的胰岛β细胞功能障碍
  • 批准号:
    9780698
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Islet Beta-Cell Dysfunction Under Metabolic Stress
代谢压力下的胰岛β细胞功能障碍
  • 批准号:
    10045502
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Islet Beta-Cell Dysfunction Under Metabolic Stress
代谢压力下的胰岛β细胞功能障碍
  • 批准号:
    10436768
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel Regulators of Islet Beta-Cell Function in Health and Diabetes
健康和糖尿病中胰岛β细胞功能的新型调节剂
  • 批准号:
    9339579
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Novel Regulators of Islet Beta-Cell Function in Health and Diabetes
健康和糖尿病中胰岛β细胞功能的新型调节剂
  • 批准号:
    8921631
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Islet Beta Cell Dysfunction in Diabetes
糖尿病胰岛β细胞功能障碍的机制
  • 批准号:
    8394622
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Islet Beta Cell Dysfunction in Diabetes
糖尿病胰岛β细胞功能障碍的机制
  • 批准号:
    7786030
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Islet Beta Cell Dysfunction in Diabetes
糖尿病胰岛β细胞功能障碍的机制
  • 批准号:
    7907735
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了